OR WAIT 15 SECS
The investment will increase production lines for bulk drug substance and will add a fill/finish production line to the site.
Fujifilm Corporation announced on June 9, 2020 that is investing $928 million into the Denmark site of Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics and advanced therapies.
According to a company press release, the investment will increase production lines for bulk drug substance by adding on six mammalian cell bioreactors, bringing the total to 12 x 20,000-L bioreactors by Fall 2023. Additionally, the investment will add a fill/finish production line to the site featuring a fully automated system capable of producing up to approximately 35 million units per annum for large-scale production.
“Our culture of innovation and reputation of manufacturing excellence ensures our rapid growth to better serve the healthcare community,” said Takatoshi Ishikawa, executive vice-president, general manager of bio-CDMO division, Fujifilm Corporation, in the press release. “Since the acquisition of the Denmark site last year, the facility's strong manufacturing track-record, coupled with Fujifilm Diosynth Biotechnologies' technologies enabling a stable supply of high-quality biopharmaceuticals, has led to new orders not only from existing clients, but also new clients, contributing to our rapid business expansion”
“With the addition of world-class assets enabling us to scale production volumes to fit both small and large batches, the capital infusion allows us to deliver on our promise to support our partners from pre-clinical through to commercialization,” said Martin Meeson, CEO, Fujifilm Diosynth Biotechnologies, in the press release. “Moreover, we are able to support our partners in manufacturing lifesaving therapies to patients around the world.”